CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用于抗原递送的可生物降解纳米平台：第 II 部分——用于肿瘤免疫治疗的纳米颗粒、水凝胶与微针
英文原题：Biodegradable nanoplatforms for antigen delivery: part II - nanoparticles, hydrogels, and microneedles for cancer immunotherapy.
查看英文原题
Biodegradable nanoplatforms for antigen delivery: part II - nanoparticles, hydrogels, and microneedles for cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
我们回顾了 CAR-T 细胞疗法在最常见的血液系统恶性肿瘤中的当前可行性和挑战，并根据疾病类型和治疗优先级对其进行了分类，以指导临床医生和研究人员进一步应用和研究 CAR-T 细胞。
研究思路结论见上方概要
背景
近年来，CAR-T（CAR-T）细胞疗法在治疗难治性或复发性血液系统恶性肿瘤患者方面取得了突破性进展。然而，适合接受CAR-T 细胞治疗的患者识别仍有待改进。涵盖领域：CAR-T 细胞疗法在血液系统恶性肿瘤中已展现出卓越疗效；然而，在根据患者特征评估来决定何时应用CAR-T 细胞方面，观点仍存在争议。
展开英文摘要原文
INTRODUCTION: In recent years, chimeric antigen receptor T (CAR-T) cell therapy has resulted in a breakthrough in the treatment of patients with refractory or relapsed hematological malignancies.
However, the identification of patients suitable for CAR-T cell therapy needs to be improved. AREASCOVERED: CAR-T cell therapy has demonstrated excellent efficacy in hematological malignancies; however, views on determining when to apply CAR-T cells in terms of the evaluation of patient characteristics remain controversial.
EXPERT OPINION: We reviewed the current feasibility and challenges of CAR-T cell therapy in the most common hematological malignancies and classified them according to disease type and treatment priority, to guide clinicians and researchers in applying and investigating CAR-T cells further.
论文信息
- 作者
- Burgos JM、Vega E、García ML、Pujol M、Sánchez-López E、Souto EB
- 单位
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.Spain
- 文献类型
- 综述
- 期刊
- Expert opinion on drug delivery2024 Sep
- 原文标识
- PubMed 39245925 · DOI 10.1080/17425247.2024.2400291